The American Association of Immunologists has selected Fred Hutchinson Cancer Research Center’s Dr. Philip Greenberg, a world expert in cancer immunotherapy, as an AAI 2019 Distinguished Fellow. He is among 52 researchers selected for the inaugural class of fellows.
Immunotherapy, an offshoot of Fred Hutch’s pioneering work in bone marrow transplantation, harnesses the body’s immune system to eliminate cancer cells.
Greenberg, head of the Program in Immunology at Fred Hutch, is also a professor of medicine and immunology at the University of Washington School of Medicine and a member of the Parker Institute for Cancer Immunotherapy. He specializes in a form of immunotherapy called T-cell therapy. His early discoveries about how to target diseases with these immune cells have been foundational for this field.
In the lab and the clinic, Greenberg’s team continues to develop new strategies for genetically reprogramming a patient’s T cells to recognize and kill cancers. They are creating new T-cell therapies for patients with acute myeloid leukemia, ovarian cancer, pancreatic cancer and other malignancies.